Sciety’s Post

Thanks to Ryan Dolan and Kelly Provost from CFGI for hosting a fun Life Sciences event last night at the ICA in Boston. Some key takeaways from an informative panel: 1) The life sciences IPO market has been relatively weak the past few years, with only 10 or so IPOs / year. Historically, in an "average" year, there are 30 - 40 life sciences IPOs. 2) The 3 life sciences IPOs that will price this week are a positive sign / trend. 3) Per Susanne Mulligan, 2025 should be a "good" year for life sciences IPOs. This will be driven by combination of factors, including: a) likely 25bp interest rate cut b) getting past the presidential election (the market does not like uncertainty) c) possible change in leadership at FTC (which should result in return of big M&A deals in life sciences) d) large back-log of well-funded, high-quality life sciences companies that are in the IPO queue (per Bruce Booth, roughly 150 private companies have raised cross-over rounds in the past few years, and many (1/3?) of these are currently on file confidentially with the SEC) 4) If Susanne is right, then Ryan's golf game is going to take a major hit in 2025. (Sorry Ryan!)

The Life Sciences industry has gone through peaks and troughs in the last year with very little or next to no growth shown for 2023. This however does not seem to be the case for 2024. A record number was raised with venture capital and private equity firms in January and February alone. The traction across the board is picking up momentum with companies merging and entering exclusive agreements. While it will take some time for the money to spread through the industry, it is certainly a positive indicator of what Life Sciences professionals can expect going forward. The CDMO industry continues to build with projections of reaching $322.7 Billion by 2033. Full article - https://lnkd.in/eXyeUsXP #cdmo #lifesciences #growth

🧬 LIFE SCIENCES IPO TREND ALERT 📈 We recently hosted Life Sciences IPO Summits in the Bay Area and Boston, and our featured industry panelists highlighted some promising trends ⬇️ • While Q1 activity levels were near pre-pandemic levels (with $1.2 billion raised in the first six weeks alone) — since then, investors have been wary, though there is still optimism • If being public is your goal, it’s important to get IPO ready NOW so you can act quickly when the market opens • Securing crossover financing, early buy-in from leaders and investors, and thorough preparation with the right team are crucial Getting the best advisory team on board should be a top priority. With experience on over 100 Life Science IPOs, we can help you build the right foundation for a successful public market entrance. Connect with our experts Aleks Zabreyko and Randa Ghantous, CPA or comment below to learn more!

Opportuna and infinitas capital highlighted in Bloomberg's latest article on the evolving secondaries market, which speaks to the demand for innovative approaches to liquidity in private markets. We think there is 15-20y of backlog in both the US and Europe. 👉 For those interested in deeper insights and the trends shaping private markets, I share exclusive updates through my Beehiiv newsletter. Join our community here: https://lnkd.in/eY8KuN9N 👉 For those interested in selling a stake or simply knowing more about the asset class, you can contact us here: https://lnkd.in/eaSwVBXW #VentureSecondaries #FamilyOffices #BloombergFeature #Newsletter #PrivateMarkets

As the dust settles from years of soaring valuations, our focus shifts to new expectations in 2024. At #LSIUSA24, our expert panelists will unpack the latest developments in valuation and financing, sharing forecasts and current trends that address the 2024 outlook, and provide a deep dive into how these shifts will affect both current and future investment landscapes. We’ll hear perspectives from: • Rik Vandevenne (Moderator), Managing Director, RC Capital, a Healthcare focused growth equity fund, currently investing out of its seventh fund. • Rebecca Raabe, Investment Partner, SPRIG Equity, a growth equity and late-stage venture capital firm dedicated to improving patient outcomes by partnering with best-in-class teams and technologies in the medical technology sector. • Paul McCreadie, Partner & COO Arboretum Ventures, a venture capital firm specializing in the healthcare sector investing throughout the United States, but with a preference for Midwest opportunities. • Matthew Schopp, Senior Director, Business Development, Zimmer Biomet, a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We are still accepting registrations for LSI USA ‘24 on March 18-22 in Dana Point, California. Visit our website to learn more and secure your spot: https://lnkd.in/gjgMpMBh

Chris Garabedian, CEO, Xontogeny & Portfolio Manager, PXV Fund, Alyssa Abo, MD, MBA, & Suzy Engwall 🚀 Thrilled to catch up with Chris Garabedian, CEO of Xontogeny and Portfolio Manager of PxV Fund, alongside industry pros Alyssa Abo, MD, MBA, and Suzy Engwall, at the HLTH Conference! We dove into some powerful trends driving healthcare innovation and investment—here’s a taste of the conversation: 🌟 On the Hunt for Breakout Companies: Chris is laser-focused on identifying companies on the verge of breakout, paying close attention to their customer base and the real traction they’re making in the market. 🔥 A Wave of Mergers & Acquisitions: A recent conversation with a healthcare leader revealed a startling reality—50% of today’s startups might not be around next year. This climate is sparking a wave of matchmaking between startups and suitors, as companies look for strategic partners to ensure longevity and success. 🎯 Why Team Matters: When investing in early-stage companies, Chris is all about the people. His focus? Founders’ networks, their track records, and what sets their solutions apart in a competitive landscape. ⚡ The Rise of Consumer-Centric Healthcare: The consumerization of healthcare is sparking incredible growth and reshaping the market, but it’s still challenging to pick winners. Healthcare remains a complex arena where innovative technology is essential, but standard reimbursement models continue to be the backbone of long-term viability. Exciting times ahead as we witness the rapid disruption of healthcare. 📈💥 #HLTH2024 #healthcareinnovation #venturecapital #Xontogeny #healthcarestartups #ConsumerHealth #mergersandacquisitions #healthtech Planetary Health First Mars Next #planetaryhealthfirstmarsnext

Chris Garabedian, CEO, Xontogeny & Portfolio Manager, PxV Fund, Alyssa Abo, MD, MBA, & Suzy Engwall 🚀 Thrilled to catch up with Chris Garabedian, CEO of Xontogeny and Portfolio Manager of PxV Fund, alongside industry pros Alyssa Abo, MD, MBA, and Suzy Engwall, at the HLTH Conference! We dove into some powerful trends driving healthcare innovation and investment—here’s a taste of the conversation: 🌟 On the Hunt for Breakout Companies: Chris is laser-focused on identifying companies on the verge of breakout, paying close attention to their customer base and the real traction they’re making in the market. 🔥 A Wave of Mergers & Acquisitions: A recent conversation with a healthcare leader revealed a startling reality—50% of today’s startups might not be around next year. This climate is sparking a wave of matchmaking between startups and suitors, as companies look for strategic partners to ensure longevity and success. 🎯 Why Team Matters: When investing in early-stage companies, Chris is all about the people. His focus? Founders’ networks, their track records, and what sets their solutions apart in a competitive landscape. ⚡ The Rise of Consumer-Centric Healthcare: The consumerization of healthcare is sparking incredible growth and reshaping the market, but it’s still challenging to pick winners. Healthcare remains a complex arena where innovative technology is essential, but standard reimbursement models continue to be the backbone of long-term viability. Exciting times ahead as we witness the rapid disruption of healthcare. 📈💥 #HLTH2024 #healthcareinnovation #venturecapital #Xontogeny #healthcarestartups #ConsumerHealth #mergersandacquisitions #healthtech Planetary Health First Mars Next #planetaryhealthfirstmarsnext

🌍 The Family Office landscape is evolving, and we're seeing a major trend emerging: Family Offices are flocking to the $140 billion market for secondary sales. 📈 According to Bloomberg, more and more Family Offices are exploring secondary transactions as a strategy to increase liquidity and diversify their holdings in private investments. This shift reflects a growing sophistication among Family Offices in navigating the alternative investment landscape—something we at Ledgex have been prepared for since day one. Our platform is designed to support these evolving strategies by simplifying complex data management and providing a clear view of all investment types, including secondary transactions. As Family Offices continue to expand their focus on alternative investments, tools that can handle this complexity are no longer just a luxury—they are essential. If you’re curious about how the secondary sales market is impacting Family Offices and how Ledgex can help navigate these opportunities, check out the full article here: https://lnkd.in/ePB2x4JC #FamilyOffices #AlternativeInvestments #SecondaryMarket #Ledgex #WealthManagement #InnovationInFinance #PrivateWealth Nicole Eberhardt, Peter Cunha, Wendy McCoy, Christopher McCoy, Brian Nickerson

Our CEO Robin Lauber highlights that "the timing seems right" to invest in secondary markets. Read the full Bloomberg News article here: https://lnkd.in/gmwXN_En With traditional liquidity channels tightening, secondary sales offer family offices access to high growth, mature private companies at attractive valuations. In this context, we launched Opportuna, our new venture secondaries vehicle. Reasons why we are drawn to secondaries: * Unlocking liquidity in constrained markets * Gaining access to established companies with proven growth * Continuation funds provide stability and upside potential #privateequity #venturecapital #secondarymarket #familyoffice #venturesecondaries

With less than a week until our third annual Cavenagh Health Investor Breakfast, meet some of our distinguished panellists! As we aim to explore answers to the critical question: “From Defense to Offence: Is Now the Time to Shift Investment Strategies?” our panel of industry leaders will discuss strategies to navigate uncertainty in our current high-stakes investment landscape, Our first panellist is Debora Dumont, co-founder and Managing Partner of Bioqube Ventures. With a wealth of experience as a board member across biotech companies and her involvement in numerous international venture capital transactions, Debora brings invaluable insights and expertise across the industry to the panel. Our second panellist is the Managing Partner at Wellington Partners, Regina Hodits. Since joining the industry in 2000, she has become an influential investor in the European VC sector, specialising in early-stage and growth deals within Life Sciences. On the panel, we'll also welcome Ingrid Teigland Akay, MD MBA, Managing Partner at Hadean Ventures, who is also a medical doctor and experienced investment professional with a background in healthcare, consumer goods, and technology. This is set to be a morning packed with insightful discussions on navigating the complexities of today's market. If you’re an investor interested in attending, please contact Stephanie Murtagh for details. #HealthcareInvestment #LifeSciences #InvestmentStrategies #CavenaghHealth #JefferiesHealthcareBreakfast #ImpactInvesting #Biotech